ALK and non-small cell lung carcinoma: Additionally, targeted therapies for the anaplastic lymphoma kinase (ALK) fusion gene, c-ros 1 (ROS1) fusion gene, BRAF mutation, mesenchymal-epithelial transition (MET) exon 14 skipping mutation, RET mutation, and KRAS mutation are available in NSCLC.